Imagery as Biomarker of Gout (TIGER)
Hyperuricemia
About this trial
This is an interventional prevention trial for Hyperuricemia focused on measuring Dual-energy computed tomography, hyperuricemia, gout, monosodium urate crystals
Eligibility Criteria
Inclusion Criteria:
- Serum urate level ≥ 80 mg/L on inclusion,
- No current or previous clinical symptoms of gout (including clinically apparent flares or tophus),
- Between 18 and 80 years old,
- Able to give informed consent.
Exclusion Criteria:
- GFR (glomerular filtration rate) <30 ml / min / 1.73 m² or dialysis,
- Serious illness with a poor prognosis of less than 5 years,
- Autoimmune inflammatory arthritis,
- Change of geographical area within 5 years,
- Previous analysis of synovial fluid showing crystals of MSU,
- Presence of subcutaneous tophi,
- Taking a hypouricaemic treatment (allopurinol, probenecid, benzbromarone, febuxostat, lesinurad), canakinumab, anakinra or colchicine,
- Uricemia observed only after an acute decompensation of comorbidity
- Pregnant or breastfeeding women
Sites / Locations
- Lille Catholic HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Patient at high risk for gout due to elevated serum urate concentrations (≥ 8 mg/dL)
Patients at high risk for gout due to elevated serum urate concentrations (≥ 8 mg/dL) will be included. The participants included will be followed for a period of 60 months, with an initial visit, a final visit as well as an additional visit in case of suspicion of gout. The presence of symptoms suggestive of gout will be evaluated during regular contact with the participants: a telephone call every 6 months as well as a postal or electronic mail every 3 months. Participants will be asked to contact the investigator if new symptoms or relevant medical events occur. Blood (32.5 ml maximum) and urine (4 ml) samples will be taken from participants who have given their specific consent for a biological collection with a particular genetic aim.